Martin Preyer, Ph.D.

Executive Director, Biotherapeutics at Evolveimmune Therapeutics

Speaker

Martin Preyer is currently the Executive Director, Biotherapeutics at Evolveimmune Therapeutics, where he is leading the biologics drug discovery and protein engineering team. Before joining Evolveimmune, Martin has led various aspects of biologics drug discovery including the development of ADCs and the engineering of novel bispecific antibody technologies. Among others, he was the head of protein sciences at Revitope Oncology, where he developed a novel platform of protease-activatable T cell engagers for cancer immunotherapy. Martin received his PhD from the University of Natural Resources and Life Sciences in Vienna, Austria, and completed his postdoctoral training in the Laboratory of Genetics at the Salk Institute in La Jolla, CA.